Efficacy of dupilumab in the treatment of severe vulvar pruritus associated with lichen sclerosus et atrophicus: a case report.

Front Med (Lausanne)

Department of Dermatology and Venereology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.

Published: June 2024

AI Article Synopsis

  • * Treatment can be challenging due to its tendency to recur, with potent topical corticosteroids being the primary option, though newer therapies like dupilumab are emerging.
  • * A case study of a 61-year-old woman showed that after four months of dupilumab treatment, she experienced significant relief from vulvar itching and skin thinning, without any negative side effects.

Article Abstract

Lichen sclerosus et atrophicus (LSA) is a chronic inflammatory skin lesion with an undefined cause. It is more commonly found in the genital area, particularly in adolescents, premenopausal women and postmenopausal women. LSA is difficult to treat and often recurs. The primary treatment for LSA involves the administration of potent topical corticosteroids. Dupilumab is increasingly being used for the treatment of itching in non-atopic dermatitis patients but there are few reports on its use for the treatment of LSA. Here, we present a case of LSA in a 61-year-old woman with extensive vulvar itching. Over four months of dupilumab therapy, significant therapeutic effects were observed, including vulvar skin thinning and pruritus relief without adverse reactions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233783PMC
http://dx.doi.org/10.3389/fmed.2024.1422389DOI Listing

Publication Analysis

Top Keywords

lichen sclerosus
8
sclerosus atrophicus
8
treatment lsa
8
lsa
5
efficacy dupilumab
4
treatment
4
dupilumab treatment
4
treatment severe
4
severe vulvar
4
vulvar pruritus
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!